Targeting blood-brain-barrier transcytosis – perspectives for drug delivery
Efficient transcytosis across the blood-brain-barrier (BBB) is an important strategy for accessing drug targets within the central nervous system (CNS). Despite extensive research the number of studies reporting successful delivery of macromolecules or macromolecular complexes to the CNS has remaine...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2016
|
| _version_ | 1797064337278369792 |
|---|---|
| author | Mäger, I Meyer, A Li, J Lenter, M Hildebrandt, T Leparc, G Wood, M |
| author_facet | Mäger, I Meyer, A Li, J Lenter, M Hildebrandt, T Leparc, G Wood, M |
| author_sort | Mäger, I |
| collection | OXFORD |
| description | Efficient transcytosis across the blood-brain-barrier (BBB) is an important strategy for accessing drug targets within the central nervous system (CNS). Despite extensive research the number of studies reporting successful delivery of macromolecules or macromolecular complexes to the CNS has remained very low. In order to expand current research it is important to know which receptors are selective and abundant on the BBB so that novel CNS-targeting antibodies or other ligands could be developed, targeting those receptors for transcytosis. To do that, we have set up a proteomics- and transcriptomics-based workflow within the COMPACT project (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets) of the Innovative Medicines Initiative (IMI) of the EU. Here we summarise our overall strategy in endothelial transcytosis research, describe in detail the related challenges, and discuss future perspectives of these studies. |
| first_indexed | 2024-03-06T21:12:49Z |
| format | Journal article |
| id | oxford-uuid:3ec2c5d2-d789-4681-b405-761d648de311 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T21:12:49Z |
| publishDate | 2016 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:3ec2c5d2-d789-4681-b405-761d648de3112022-03-26T14:27:32ZTargeting blood-brain-barrier transcytosis – perspectives for drug deliveryJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3ec2c5d2-d789-4681-b405-761d648de311Symplectic Elements at OxfordElsevier2016Mäger, IMeyer, ALi, JLenter, MHildebrandt, TLeparc, GWood, MEfficient transcytosis across the blood-brain-barrier (BBB) is an important strategy for accessing drug targets within the central nervous system (CNS). Despite extensive research the number of studies reporting successful delivery of macromolecules or macromolecular complexes to the CNS has remained very low. In order to expand current research it is important to know which receptors are selective and abundant on the BBB so that novel CNS-targeting antibodies or other ligands could be developed, targeting those receptors for transcytosis. To do that, we have set up a proteomics- and transcriptomics-based workflow within the COMPACT project (Collaboration on the Optimization of Macromolecular Pharmaceutical Access to Cellular Targets) of the Innovative Medicines Initiative (IMI) of the EU. Here we summarise our overall strategy in endothelial transcytosis research, describe in detail the related challenges, and discuss future perspectives of these studies. |
| spellingShingle | Mäger, I Meyer, A Li, J Lenter, M Hildebrandt, T Leparc, G Wood, M Targeting blood-brain-barrier transcytosis – perspectives for drug delivery |
| title | Targeting blood-brain-barrier transcytosis – perspectives for drug delivery |
| title_full | Targeting blood-brain-barrier transcytosis – perspectives for drug delivery |
| title_fullStr | Targeting blood-brain-barrier transcytosis – perspectives for drug delivery |
| title_full_unstemmed | Targeting blood-brain-barrier transcytosis – perspectives for drug delivery |
| title_short | Targeting blood-brain-barrier transcytosis – perspectives for drug delivery |
| title_sort | targeting blood brain barrier transcytosis perspectives for drug delivery |
| work_keys_str_mv | AT mageri targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery AT meyera targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery AT lij targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery AT lenterm targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery AT hildebrandtt targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery AT leparcg targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery AT woodm targetingbloodbrainbarriertranscytosisperspectivesfordrugdelivery |